NANOS Inc.

NANOS Inc.NANOS Inc.NANOS Inc.

NANOS Inc.

NANOS Inc.NANOS Inc.NANOS Inc.

Next-Generation Nitric Oxide Therapies

Next-Generation Nitric Oxide TherapiesNext-Generation Nitric Oxide TherapiesNext-Generation Nitric Oxide Therapies

Technology Powered by Intracellular NO Store

Learn more

About us

NANOS Inc. is a biotechnology company, based in LLU’s N3Eight Incubator Program and supported by NIH STTR funding. We are dedicated to advancing the NANOS theory and translating it into innovative treatments that restore blood flow, protect organs, and improve patient outcomes across a wide range of serious and life-threatening conditions.

Welcome to NANOS Inc.

Mission

Product Pipelines

Product Pipelines

We are on a mission to harness the Nitrodilator-activated intracellular NO Store (NANOS) within the body to improve patient care. Our vision is a future where NANOS-based therapies are readily available to restore blood flow, protect organs, and accelerate recovery worldwide.

Product Pipelines

Product Pipelines

Product Pipelines

Transdermal Patch


Ointment


Tablet


Eyedrop 

Team

Product Pipelines

Team

Our team combines decades of experience in NO biology, cardiovascular physiology, and product development. We collaborate closely with clinicians, academic partners, and industry stakeholders to understand unmet clinical needs and design NANOS-based therapies that are effective, easy to use, and ready for real-world care.

NANOS Clinical Applications

Angina

Angina is an ischemic heart disease that affects ~10 million patients in the U.S., and more than 130 million worldwide. Thirty to 40% of these patients suffer from microvascular angina, for which there is no interventional treatment. Nitroglycerin (NTG) and its organic nitrate derivatives such as the oral isosorbides, have been the first-line medical treatment for angina for over a century. However, all formulations of NTG and organic nitrates suffer from the phenomenon of tolerance, a loss of therapeutic response to the medication following frequent use. Tolerance develops within as little as 12 hours of continuous use in patients as well as healthy humans and animals. To mitigate tolerance, patients must endure 10- to 12-hour drug-free intervals that expose them to reduced protection, occurrences of rebound angina and myocardial ischemia, and decreased exercise capacity. Despite being first-line therapies, the need to allow for drug-free intervals in order to avoid tolerance limits the therapeutic usefulness of NTG and related organic nitrates. NANOS Inc. is developing nitroglycerin–nitrite combination therapies that harness the Nitrodilator-Activated intracellular NO Store (NANOS) to treat angina while minimizing or preventing nitrate tolerance.

Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) occur during the lifetime of about one-third of all diabetes patients, resulting in approximately 100,000 lower limb amputations and  >$9 billion in healthcare burden in the U.S. each year.  Currently there are no FDA-approved pharmacologic therapies that target the underlying microvascular dysfunction responsible for impaired DFU healing, or the ~40% chance of recurrence. DFUs are associated with loss of endothelial-mediated dilation and microvascular dysfunction. A therapy that safely increases local blood flow could transform DFU care. Nitroglycerin (NTG) is a potent vasodilator with an established cardiovascular safety record, but its chronic use is limited by tolerance that develops within 8 to 12 hours. The NANOS, Inc therapeutic platform is based on the discovery that nitrite can prevent tolerance to NTG, improving and prolonging its vasodilatory effects. NANOS, Inc. is developing a proprietary first-in-class transdermal patch (NANOSkin) that combines NTG with nitrite and thus enhances local vasodilation to promote wound healing and reduce rates of recurrence. 

Others

Glaucoma, 

Chemotherapy,

... 

Science

NANOS Theory

The NANOS theory (Nitrodilator-Activated Intracellular NO Store) proposes that cells contain a substantial, underutilized intracellular store of nitric oxide (NO) that can be selectively “awakened” by endogenous and exogenous nitrodilators such as nitrosothiols and nitroglycerin. Rather than viewing these nitrodilators as the primary source of NO, NANOS highlights their role as triggers that mobilize this internal NO reservoir, improving microvascular blood flow, protecting organs, and overcoming classic problems like nitroglycerin tolerance. This framework reframes NO from a fleeting signaling molecule into a targetable, rechargeable store, opening new possibilities for therapy across a wide range of diseases.

Research Highlights

  • Liu T.; Zhang M.; Li Q.; Schroeder H.; Power G.G.; and Blood A.B. Nitrite reverses nitroglycerin tolerance via repletion of a nitrodilator-activated nitric oxide store in vascular smooth muscle cells. Redox Biology, 2025, 80:103513
  • Liu T.; Schroeder H.; Power G.G.; Blood A.B. A physiologically relevant role for NO stored in vascular smooth muscle cells- A novel theory of vascular NO signaling. Redox Biology, 2022, 53:102327.
  • Liu T.; Zhang M.; Mukosera, G.T. ; Power G.G.; Li Q.; Dan B.; Blood A.B. L-NAME releases NO and potentiates Nitroglycerin-mediated vasodilation. Redox Biology, 2019, 26:101238. 

Patents

PCT/US Patent Application US20250205276A1 – Method patent for therapeutic use of combinations of nitrodilators (e.g., nitroglycerin) and nitro-group compounds (e.g., nitrite) to target a broad range of microvascular diseases and related conditions. Inventors: Taiming Liu and Arlin Blood.

Our Team

Taiming Liu PhD

Taiming Liu PhD

Taiming Liu PhD

CEO & Co-Founder, NANOS Inc. 

Associate Professor of Pediatrics

Loma Linda University School of Medicine

Loma Linda, California, USA 

Arlin Blood PhD

Taiming Liu PhD

Taiming Liu PhD

CFO & Co-Founder, NANOS Inc. 

Associate Professor, Center for Perinatal Biology & Departments of Basic Sciences and Pediatrics, Loma Linda University School of Medicine

Contact Us

Have questions about our NANOS platform? We’re here to help.

We welcome inquiries and collaboration opportunities—please reach out anytime.

NANOS Inc.

11219 Anderson St, Loma Linda, CA 92354. USA

taimingliu@nanospharm.com

Hours

Today

Closed

Drop us a line!

Attach Files
Attachments (0)

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

NANOS Inc

11219 Anderson St, Loma Linda, CA 92354

Copyright © 2025 NANOS Inc - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept